intranasal delivery comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-01. Numbers and descriptions here follow the published literature rather than marketing material.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
===== Ground glass opacities ===== Acute: Alveolar hemorrhage syndromes Pulmonary edema Hypersensitivity pneumonitis Acute inhalational exposures Drug-induced lung diseases Acute interstitial pneumonia Chronic: Nonspecific interstitial pneumonia Respiratory bronchiolitis-associated interstitial lung disease Desquamative interstitial pneumonia Drug-induced lung diseases Pulmonary alveolar proteinosis
Methamphetamine is a chiral compound with two enantiomers, dextromethamphetamine and levomethamphetamine. At room temperature, the free base of methamphetamine is a clear and colorless liquid with an odor characteristic of geranium leaves. It is soluble in diethyl ether and ethanol as well as miscible with chloroform.
Laird announced that the first U.S. forces to leave South Vietnam would be 900 infantrymen from the 9th Infantry Division. Prime Minister of Laos Souvanna Phouma acknowledged that U.S. aircraft regularly carried out bombing missions over Laos.
Sources: en.wikipedia.org
=== 2012: Deaths of senior staff === On 19 November 2012, the senior staff members Jorge Ivan Arango Herrera and Carl Magnus Lindgren were killed on Chai Wan Road, Hong Kong, when their taxi was hit by two buses. The taxi driver, Wong Kim-chung, was also killed, and a further 56 people were injured.
Surfactants play an important role in droplet-based microfluidics. The main purpose of using a surfactant is to reduce the interfacial tension between the dispersed phase (droplet phase, typically aqueous) and continuous phase (carrier liquid, typically oil) by adsorbing at interfaces and preventing droplets from coalescing with each other, therefore stabilizing the droplets in a stable emulsion state, which allows for longer storage times in delay-lines, reservoirs, or vials. Without using surfactants, the unstable emulsions will eventually evolve into separate phases to reduce the overall energy of the system. Surface chemistry cannot be ignored in microfluidics as the interfacial tension becomes a major consideration among microscale droplets. Linas Mazutis and Andrew D. Griffiths presented a method that used surfactants to achieve a selective and highly controllable coalescence without external manipulation. They manipulate the contact time and the interfacial surfactant coverage of a drop pair to control droplet fusion. The larger the difference percentage of the interfacial surfactant coverage between two droplets, the less likely coalescence will occur. This method allowed researchers to add reagents to droplets in a different way and further study the emulsification.
=== European Union === The European Union defines a VOC as "any organic compound as well as the fraction of creosote, having at 293.15 K a vapour pressure of 0.01 kPa or more, or having a corresponding volatility under the particular conditions of use;". The VOC Solvents Emissions Directive was the main policy instrument for the reduction of industrial emissions of volatile organic compounds (VOCs) in the European Union. It covers a wide range of solvent-using activities, e.g. printing, surface cleaning, vehicle coating, dry cleaning and manufacture of footwear and pharmaceutical products. The VOC Solvents Emissions Directive requires installations in which such activities are applied to comply either with the emission limit values set out in the Directive or with the requirements of the so-called reduction scheme. Article 13 of The Paints Directive, approved in 2004, amended the original VOC Solvents Emissions Directive and limits the use of organic solvents in decorative paints and varnishes and in vehicle finishing products. The Paints Directive sets out maximum VOC content limit values for paints and varnishes in certain applications. The Solvents Emissions Directive was replaced by the Industrial Emissions Directive from 2013.
Semiconductors, metals, and ceramics are used today to form highly complex systems, such as integrated electronic circuits, optoelectronic devices, and magnetic and optical mass storage media. Semiconductors are a traditional example of these types of materials. They are materials that have properties that are intermediate between conductors and insulators. Their electrical conductivities are very sensitive to the concentration of impurities, which allows the use of doping to achieve desirable electronic properties. Hence, semiconductors form the basis of the traditional computer. This field also includes new areas of research such as superconducting materials, spintronics, metamaterials, etc. The study of these materials involves knowledge of materials science and solid-state physics or condensed matter physics.
Sources: en.wikipedia.org
== Side effects == The Z-drugs are notable for producing side effects such as pronounced amnesia and more rarely hallucinations, especially when used in large doses. On rare occasions, these drugs can produce a fugue state, wherein the patient sleepwalks and may perform relatively complex actions, including cooking meals or driving cars, while effectively unconscious and with no recollection of the events upon awakening. While this effect is rare (and has also been reported to occur with some of the older sedative drugs such as temazepam and secobarbital), it can be potentially hazardous, and so further development of this class of drugs has continued in an effort to find new compounds with further improved profiles. Daytime withdrawal-related anxiety can also occur from chronic nightly nonbenzodiazepine hypnotic usage such as with zopiclone. Side effects can differ within the drug class due to differences in metabolism and pharmacology. For example, long-acting benzodiazepines have problems of drug accumulation especially in the elderly or those with liver disease, and shorter-acting benzodiazepines have a higher risk of more severe withdrawal symptoms. In the case of the nonbenzodiazepines, zaleplon may be the safest in terms of next-day sedation, and − unlike zolpidem and zopiclone − zaleplon has been found to have no association with increased motor vehicle accidents even when taken for middle-of-the-night insomnia due to its ultrashort elimination half-life.
Since precipitation from an aqueous medium, by addition of ammonium sulfate or polyethylene glycol, is often used to purify enzymes, the CLEA methodology essentially combines purification and immobilization into a single unit operation that does not require a highly pure enzyme. It could be used, for example, for the direct isolation of an enzyme, in a purified and immobilized form suitable for performing biotransformations, from a crude fermentation broth. CLEAs are very attractive biocatalysts, owing to their facile, inexpensive and effective production method. They can readily be reused and exhibit improved stability and performance. The methodology is applicable to essentially any enzyme, including cofactor dependent oxidoreductases. Application to penicillin acylase used in antibiotic synthesis showed large improvements over other type of biocatalysts. The potential applications of CLEAs are numerous and include:
=== Laboratory applications === Other applications include phosphorothioate-based ligase-independent cloning, sequence saturation mutagenesis, no-SCAR genome editing, nucleotide analog interference mapping, and incremental truncation for the creation of hybrid enzymes, and antibody-oligonucleotide conjugates.
== Treatment == The treatment of burn scar contracture and deformity begins upon hospitalization. Wound care and functional outcomes can be predicted from the initial assessment of wound depth and location. Epidermal and partial thickness wounds heal in 1 to 3 weeks through epithelial migration from the wound edges and epithelial budding from the appendages of the sweat and hair glands. These wounds pose only a small risk of contracture and hypertrophic scarring. Full-thickness (FT) injuries cause dermal wound healing, which is characterized by maturation (contraction and increased tensile strength), proliferation (collagen synthesis leading to wound closure), and inflammation (edema). FT wounds heal by excision and grafting, contracture, or epithelial ingrowths from the margins. Because of insufficient tissue length and extensibility, severe damage to the integument system may result in significant impairment and disability. By using stress-strain curves, where stress is equal to force and strain is equal to tissue elongation, mechanical engineering principles can be used to assess the biomechanics of skin and scars. Stretching an adult burn scar is similar to stretching a tendon in terms of elasticity. On the other hand, persistent force applied to tissue will cause it to elongate, which will lead to a plastic change in length and an increase in range of motion. Fast and forceful stress is much less effective than a gentle, prolonged stretch that the patient can tolerate.
In 2024, Lawrence Berkeley National Laboratory published a reliable way to make element 116, livermorium, using a titanium beam to irradiate a plutonium foil. This method may be useful in producing several more elements beyond Oganesson, element 118.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.